Page last updated: 2024-10-16

methane and Gastroparesis

methane has been researched along with Gastroparesis in 2 studies

Methane: The simplest saturated hydrocarbon. It is a colorless, flammable gas, slightly soluble in water. It is one of the chief constituents of natural gas and is formed in the decomposition of organic matter. (Grant & Hackh's Chemical Dictionary, 5th ed)
methane : A one-carbon compound in which the carbon is attached by single bonds to four hydrogen atoms. It is a colourless, odourless, non-toxic but flammable gas (b.p. -161degreeC).

Gastroparesis: Chronic delayed gastric emptying. Gastroparesis may be caused by motor dysfunction or paralysis of STOMACH muscles or may be associated with other systemic diseases such as DIABETES MELLITUS.

Research Excerpts

ExcerptRelevanceReference
" Overall, 79 (39 %) patients with gastroparesis had evidence of SIBO by LBT: 30 (15 %) had positive H2@90min, 53 (26 %) positive DPHBT, and 6 (3 %) positive breath methane test."3.80Small intestinal bacterial overgrowth in gastroparesis. ( George, NS; Parkman, HP; Sankineni, A, 2014)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Reddymasu, SC1
McCallum, RW1
George, NS1
Sankineni, A1
Parkman, HP1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Autonomic Neuropathy, Gastrointestinal Motility, and Inflammation in HIV[NCT02850276]Early Phase 176 participants (Actual)Interventional2015-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Reduction in Small Intestinal Bacterial Overgrowth (SIBO)

"Number of participants with reduction in Small intestinal bacterial overgrowth (SIBO) assessed with breath testing after 8 weeks of treatment.~The hydrogen breath test for the detection of small intestinal bacterial overgrowth (SIBO), obtained by having participants exhale into a plastic bag. the hydrogen content of the samples is measured using a commercially available analyzer." (NCT02850276)
Timeframe: week 8

InterventionParticipants (Count of Participants)
Pyridostigmine13

Change in Breath Test

Breath Test at week 8 as compared to baseline. Breath test results is the rise in the combined hydrogen and methane during the breath test. (NCT02850276)
Timeframe: baseline and week 8

Interventionppm (Median)
Baselineweek 8
Pyridostigmine2814

Change in IL-6 Plasma Level

Change in IL-6 plasma level at week 8 as compared to baseline. Plasma interleukin-6 (IL-6), an important inflammatory mediator which predicts mortality in HIV as well as multiple medical co-morbidities, presumably via inflammatory mechanisms. (NCT02850276)
Timeframe: Baseline and week 8

Interventionmean florescence intensity (Median)
BaselineWeek 8
Pyridostigmine30.526.5

Change in sCD14 Level

Change in sCD14 level at week 8 as compared to baseline. sCD14 is a marker of macrophage activation commonly used as an indirect measure of translocation (NCT02850276)
Timeframe: Baseline and week 8

Interventionmean florescence intensity (Median)
BaselineWeek 8
Pyridostigmine25732095

Change in TNFα Level

TNFα is a pro-inflammatory cytokine which is induced by components of translocating bacteria. Change in TNFα level at week 8 compared to baseline (NCT02850276)
Timeframe: Baseline and week 8

Interventionmean florescence intensity (Median)
Baselineweek 8
Pyridostigmine134.0117.5

Mean Percent Retention of Gastric Contents on Gastric Emptying Study

Percent retention of gastric contents on gastric emptying study. GI dysmotility calculated from gastric emptying scintigraphy - measurement of the percent retention of gastric contents at 4 hours. (NCT02850276)
Timeframe: Baseline and week 8

Interventionpercent retention of gastric contents (Mean)
Baselineweek 8
Pyridostigmine32

Medical Outcomes Study Questionnaire

Medical Outcomes Study (MOS-HIV) quality of life questionnaire. It is a 35 item questionnaire covering 11 dimensions of health including physical functioning, role functioning, pain, social functioning, emotional well-being, energy/fatigue, cognitive functioning, general health, health distress, overall QOL, and health transition. The total scale ranges from 0-100 with a higher score representing better functioning and well-being. (NCT02850276)
Timeframe: Baseline and week 8

Interventionscore on a scale (Mean)
BaselineWeek 8
Pyridostigmine66.165

The Composite Autonomic Symptom Score (COMPASS)

The gastrointestinal domain domain score of the COMPASS contains 12 items which reflect gastrointestinal symptoms of autonomic function. It is scored on a total scale of 0-28, with higher numbers reflecting worse symptoms. (NCT02850276)
Timeframe: Baseline and week 8

Interventionscore on a scale (Mean)
BaselineWeek 8
Pyridostigmine88.6

Other Studies

2 other studies available for methane and Gastroparesis

ArticleYear
Small intestinal bacterial overgrowth in gastroparesis: are there any predictors?
    Journal of clinical gastroenterology, 2010, Volume: 44, Issue:1

    Topics: Abdominal Pain; Adult; Breath Tests; Cohort Studies; Female; Gastric Emptying; Gastroparesis; Glucos

2010
Small intestinal bacterial overgrowth in gastroparesis.
    Digestive diseases and sciences, 2014, Volume: 59, Issue:3

    Topics: Adult; Biomarkers; Breath Tests; Female; Gastroparesis; Humans; Hydrogen; Intestine, Small; Lactulos

2014